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1. Introduction
Metal implants in the field of orthopaedic and trauma surgery have been used for a long time
to restore joint function, reduce pain or stabilize fractures [1-3]. Both prevention of infection
as well as integration of the implant with the host-tissue (mostly bone) are factors of concern.
The most frequently used implants for these purposes are made of metallic alloys (for plates
and nails for fracture repair and for total joint arthroplasties) and polyethylene (PE) (used in
the articulating parts of a prosthesis).
Infection of orthopaedic implants and prostheses is a medical issue that has intrigued people
since their very first use over two-and-a-half millennia ago. Since that early beginning, lack of
fixation and infection has been the major problem with such medical devices. In many cases,
it may result in serious discomfort, limb amputation, illness and in many cases it may have
even resulted in death of the patient. Even after 2500 years of medical progression we are still
not able to fully conquer these major health risks. Since they are not isolated to the field of
orthopaedics and trauma, their multi-factorial character indicates the complexity of the
problems concerning healthcare-associated infections (HAI) [4, 5].
The purpose of this chapter is to give an insight in the quest to decrease the percentage of
infections and increase the amount of osteointegration by coatings on metallic alloys in the
field of orthopaedic and trauma surgery. Finally an overview will be provided of the available
methods to examine and evaluate the properties of coatings in vitro and in vivo.
© 2013 Odekerken et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Healthcare-associated infections and orthopaedics
Healthcare-associated infections, also called nosocomial infections, are considered to be the
biggest healthcare related complication worldwide. HAI annually affects over 600 million
patients worldwide with approximately 4.1 million patients in Europe and about 1.7 million
patients in the United States [6, 7]. These infections can be related to the cause of death of a
considerable number of patients annually. Together with the tremendous economic burden of
HAI, HAI is a major point of interest in medical research.
Area # Patients
(million/yr)
Prevalence
(%)
Death
(%)
Costs
(billion)
Neonatal death rate
(caused by HAI)
Europe 4.1 7.1 3.7% (€) 7 < 5%
USA 1.7 4.5 5.8% ($) 6.5 < 5%
Worldwide > 600 8.5 - 15.5 Up to 75% in South-East
Asia and Africa
Table 1. Epidemiological data on HAI [6, 7].
With urinary tract infections as the most frequent implant related HAI in developed countries,
orthopaedic implant infections is another major sub-populations within the multifactorial
group of HAI (together with infections related to cardiovascular, neurological and gastroin‐
testinal interventions). Infections due to implantation of total hip and total knee prostheses
account for about 2% of the HAI, without taking trauma implants into account [7]. Trauma
implants or implants for fracture fixation and stabilization, like plates, screws and stabilizing
frames, have been described to have an even higher risk for infection, mainly due to the fact
that they are used to repair complex injuries and open fractures. Infection together with the
eventual loosening of an orthopaedic implant explains the limited lifespan of an orthopaedic
device (generally up to 15 years for an artificial joint [5, 8, 9]).
Since the discovery of antibiotics, (implant) infections have been reduced and implant
infections have become less lethal and can even be cured. Still, the extensive use of antibiotics
has resulted in an increasing amount of resistant bacterial strains, which makes infections
caused by those pathogens challenging. Medical device implantation remains troublesome
also in the case of orthopaedic implants.
1.2. The race for the surface
After implantation of an orthopaedic device, a competition between bacterial colonization
versus tissue integration takes place to conquer the surface of the implant. This phenomenon
is often described as "the race for the surface” (Figure 1) [10, 11].
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Figure 1. A schematic representation of “the race for the surface”, between the bacterial biofilm colonization and eu‐
karyotic cell adhesion with subsequent bone apposition on the implant surface.
The first stage of bacterial biofilm formation is the settling of a planktonic bacterium on the
surface of the implant.  After adhering to the surface,  the bacterium starts to divide and
encapsulate itself for protection against the host organism’s immune response. This layer
of protective matrix, mostly consisting out of polysaccharides, also shields the bacteria from
effective  antibiotic  treatment.  The  first  stage  of  the  biofilm  formation  is  complete  and
subsequently the present bacteria start to form colonies increasing the internal pressure in
the biofilm, which starts to expand. At a certain point the bacterial load within the mature
biofilm  becomes  so  high  that  planktonic  bacteria  are  released  from  the  biofilm.  These
bacteria can then result in the infection of the surrounding tissue or in the expansion of the
biofilm on a different location (Figure 1) [10-12]. Eukaryotic cell adhesion (e.g. adhesion of
osteoblasts)  on the  other  hand,  can result  in  implant  ingrowth by settling of  the  osteo‐
blast  on  the  implant  surface,  followed by  cell  division  and collagen matrix  production.
Eventual calcification of the collagen matrix allows bone apposition on the implant surface
(Figure 1) [10, 12]. In general the inability of the body and its immune system to cope with
infected implants is one of the biggest issues when implants are used for medical treat‐
ment.  Due to  infection,  local  bone  resorption takes  place,  leading to  bone  loss  and im‐
plant loosening. As such it is essential to treat the infection, avoiding the risk of tremendous
damage to the bone and the bony peri-implant tissue. After removal of an infected implant,
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the accompanying bone fractures, soft tissue infection, and inflammation result in fixation
issues and an increased infection risk during revision surgery [13].
1.3. Implant coatings
In order to decrease the amount of implant infections and prevent the implants from loosening,
coatings can be applied to the surface of the implant. These coatings may vary from (antibiotic)
releasing to non-releasing coatings. In general non-releasing coatings (like hydroxyapatite) are
applied by thermal-processes, while releasing coatings (like RGD or antibiotic-containing
coatings) are mostly applied to the surface by dip or spray coating, due to their limited thermal
stability.
Since the principle of the “race for the surface” dictates that early tissue integration may also
reduce the infection risk, a coating promoting tissue integration may also be regarded as a
passive method to reduce the amount of infections. In order to promote this tissue integration,
one of the biggest leaps forward in the improvement of implant fixation and “the race for the
surface” in favour of eukaryotic cells might be the use of hydroxyapatite (HA) coatings on the
surface of a metallic implant [12, 14-16]. Although in the beginning it was believed that
uncemented prostheses, including the HA-coated implants, would have a higher infection
percentage compared to implants fixated with an antibiotic-releasing bone-cement, long-term
studies showed a comparable infection percentage and a longer survival in favour of the
uncemented prosthesis [5, 17]. These HA-based coatings (and their derivatives) are still one of
the most frequently used implant coatings in the field of orthopaedic surgery and trauma,
resulting in improved implant ingrowth and a longer lifespan of the prosthesis [8]. A combined
situation of a coating with both antimicrobial and osteoconductive properties, is yet to be
found.
2. Active and passive implant coatings
2.1. Osteoconductive coatings
The definition of osteoconduction means that a material or coating “guides” the bone healing
or formation. In case of coatings this means that the bone formation is “guided” to grow or
attach to the coating surface (a passive coating) [18]. An orthopaedic implant with such a
surface treatment or coating provides an ideal substrate for bone aposition which results in
improved implant fixation and a possible prolonged lifespan, with a decreased risk of implant
loosening and possibly infection [10, 12].
2.1.1. Apatite coatings
The initial idea of hydroxyapatite (HA) coatings originated from the use of calciumphosphates
as a material to stimulate osteogenesis, like tricalciumphosphate (TCP). During the last
decades, studies have shown that HA and TCP are suitable for the production of ceramic
scaffolds to serve as a bone substitute. Studies on the stability of sintered TCP (Ca3(PO4)2) and
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HA (Ca10(PO4)6(OH)2) have shown that TCP ceramics dissolve over 10 times faster in acidic
and alkaline environments compared to HA [19]. Explaining the rationale behind the current
use of TCP for resorbable bone scaffolds and the use of HA for implant coatings.
Since the proposed use of HA as a coating, in the late 1980’s by Geesinket al.[14-16], several
implant designs have been used in the clinic, e.g. partially coated or fully coated hip implants.
Fully coated implants achieved complete bone remodeling around the implant, with very good
fixation properties. The major disadvantage of these fully coated implants was that in case of
revision surgery (either for implant infection or component failure) removal of the implant
resulted in massive bone trauma due to the fixation of the implant to the bone. By redefining
the coating location to the taper only, a good fixation could be achieved with limited problems
at the time of a revision surgery [15]. However this design allowed the formation of stress
shielding due to the pressure of the stem against the cortical wall. Due to this strain an implant
can get loose, resulting in bone loss or a cortical wall fracture. Still HA coatings sintered to an
implant surface has proven itself to be the most successful implant coating made, with 20 years
of clinical experience [8, 20].
2.1.2. Hydroxyapatite application methods for metallic surfaces
There are several ways to coat a metallic alloy, like titanium or stainless steel, with HA. The
techniques to coat such a metallic implant include; dip coating [21], sputter coating [22], pulsed
laser deposition [23], hot pressing and hot isostatic pressing [24], electrophoretic deposition
[25], electrostatic spraying [26, 27], thermal spraying [28], and sol–gel [29]. Some of these
techniques are still experimental, thermal spraying, in particular. Plasma spraying is the most
accepted method for the production of HA coatings [30]. Plasma spraying requires high
temperatures which may damage the HA crystallinity and create unwanted or amorphous
phases, with HA ablation from the coated surface as a possible result [28]. Every technique has
its advantages and disadvantages. For example, the thickness, the bonding strength and the
properties of the HA-composition may be influenced by the application technique. Techniques
such as thermal spraying and sputter coating are used for surfaces or substrates (e.g. porous
titanium implants) which are difficult to coat. Techniques such as electrophoretic deposition
and sol-gel may coat more complex substrates such as porous alloys, still the production of
crack free coatings remains challenging (Table 2).
2.2. Osteoinductive coatings
Although biomimetic HA coatings improve the osteoconductivity of metal implants, they do
not influence the osteoinductivity. In general osteoinductive coatings are described as coatings
which induce bone formation of undifferentiated cells in the surrounding tissue to ultimately
promote osteointegration of bone to the coating (active coatings). In order to promote the
differentiation of immature progenitor cells to an osteoblastic lineage, attempts to integrate
functional biological agents such as growthfactors into biomimetic coatings have been realized
[33, 34]. Several of these coatings have been studied extensively, the most important coatings
are described below.
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2.2.1. RGD coatings
Extracellular matrix proteins contain a short functional domain of three aminoacids, arginine
(R), glycine (G) and asparagine (D), the so-called RGD-domain. This domain plays an impor‐
Technique Advantage Disadvantage Thickness Ref
Sol-Gel • Coats 3D complex porous
substrates
• Low processing temperatures
• Relatively cheap
• Very thin coatings
• Processing in controlled
atmosphere
< 1 µm [29]
Sputter coating • Uniform coating thickness on flat
substrates
• Only coats visible area
• Expensive and time consuming
• Unable to coat complex 3D
porous substrates
• Risk for amorphous coating
0.02 - 2 µm [22]
Pulsed Laser
Deposition
• See sputter coating • See sputter coating 1 - 10 µm [23, 25]
Electrostatic Spray
Deposition
• Uniform coating thickness on flat
substrates
• Relatively cheap
• Only coats visible area
• Fragility
1 - 10 µm [26, 27, 31]
Electrophoretic
Deposition
Uniform coating thickness
• High deposition rates
• Coatscomplex 3D
poroussubstrates
• Cracks in coating
• High sintering temperatures
0.1 - 200 µm [25]
Thermal spraying,
Plasma spraying
• High deposition rates • Only coats visible area
Coating decomposition due to high
temperature
• Rapid cooling may result in
amorphous coating
30 – 200 µm [25, 28]
Dip Coating • Inexpensive
Coatings applied quickly
• Coatscomplex 3D
poroussubstrates
• High sintering temperatures
• Thermal expansion results in
amorphous coating
• Fragile due to thickness
0.05 - 2 mm [21, 25]
Hot Pressing,
Hot Isostatic Pressing
and Sintering
• Dense coatings • Unable to coat complex 3D
porous substrates
• Differences in coating elastisity
• Expensive
• Interaction with or changes due
to the encapsulation material
0.1 – 10 mm [24, 25, 32]
Table 2. Different coating techniques to apply hydroxyapatite (HA) on an implant.
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tant role in cell adhesion, cell proliferation and differentiation. RGD peptides coated to a
surface can initiate these processes in their direct vicinity. The major advantage of using
peptide coatings instead of protein coatings is that peptides are smaller and more stable
compared to proteins. This allows more peptides to be coated to a surface, which results in a
more dense coating. Studies have shown that the flanking amino acids in a RGD containing
peptide are of great importance for their efficiency. In vitro studies show promising results,
where RGD enhances (human) cell adhesion, proliferation and differentiation in the osteogenic
lineage [35]. An in vivo study of an HA/HA-RGD coating with antibiotic release showed that
the HA-RGD coating performed at least equally well as the HA-only coating [33]. Still these
coatings remain experimental by application.
2.2.2. BMP coatings
Bone morphogenic proteins (BMP’s), which belong to the transforming growth factor-β (TGF-
β) superfamily, are generally accepted osteoinductive additives for per-operative use to
enhance bone remodeling. Due to the lack of a local delivery system, capable of a sustained
release, relatively high dosages of BMP’s (e.g. BMP-2) are being used in the clinic. The use of
BMP’s has a locally higher incidence of tumorigenesis as a major disadvantage. Other osteo‐
genic BMP's, such as BMP-4 [36, 37] and BMP-7 [38], are also potent inducers of bone regen‐
eration. Knippenberg et al showed that BMP7, in contrast to BMP2 may be a more
chondrogenic growth factor in contrast to BMP2 which was described as a more osteogenic
growhtfactor [39]. BMP-2 works in 2 concentration dependent directions, at low dosages it
promotes bone remodeling, while at high dosage it promotes bone resorption. Therefore a low-
dose releasing BMP-2 coated implant may be the most optimal [40]. While many techniques
to incorporate BMP’s result in a burst release, they can also be incorporated into the crystal
latticework of coatings to establish a gradual release system [34, 40]. As such the incorporated
proteins can be released gradually and steadily at a low pharmacological level; not rapidly as
in a single high-dose burst [41]. In conclusion, incorporation of osteoinductive coatings may
seem attractive but, release rate, potential carcinogenesis, inactivation of the compound (e.g.
due to changes in temperature, pH), and bonding to the implant remain of concern.
3. Antimicrobial coatings
Since vascularization of infected tissue is often compromised and a bacterial biofilm is formed,
which results in poor penetration of antibiotics, systemic antibiotics are not sufficient to treat
a bone infection properly [10-12]. To achieve a local dose high enough to treat the infection,
this would involve a systemic overdose of the antibiotic (possibly resulting in kidney and liver
failure and damage to the function of the inner ear). The best solution to this problem is to
have a local delivery system, this suggests an approach for the treatment of orthopaedic
infections. Still in many cases the prosthesis can be rescued by infection treatment in situ,
without a surgical procedure [13, 42, 43]. The use of local antibiotics by antibiotic-loaded bone
cement, either as beads or spacers often placed after implant removal in the remaining infected
cavity. The general treatment procedure requires at least two surgical procedures, one to
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remove the infected implant and the surrounding affected tissue, combined with the placement
of a spacer or antibiotic-loaded beads to fill up to void [44-46]. The second operation is required
to remove the spacer or beads after a couple of weeks or months. Once the infection is regarded
as treated sufficiently, a new implant or prosthesis is implanted. If the treatment was not
successful, new beads can be placed, which will require a third operation for the removal of
the beads [44-46]. Due to the high costs and the tremendous burden for the patient a one-step
procedure would be preferable. An antimicrobial coating directly on the surface of the newly
placed implant, in case of revision surgery after infection, could prevent the infection form re-
occurring, but such a coating may also work as a prophylactic in the case of the placement of
a primary hip.
3.1. Antibiotic releasing coatings
Already in clinical use in other medical specialties (e.g. in sutures and central venous and
urinary tract cathethers), antibiotic releasing coatings remain mainly experimental in the field
of orthopaedic and trauma surgery. For orthopaedic applications gentamicin, vancomycin,
rifampicin, and tobramycin are the most frequently used local antiobiotics in case of an implant
infection. There are several published in vitro and in vivo studies based on the use of these
antibiotic drugs for an orthopaedic implant coating. Poly-L-lactide (PLLA) coatings with
rifampicin on a fracture fixation plate, placed on the tibia of rabbits, showed good results on
both antimicrobial properties and acceptance of the host-tissue within 28 days after surgery
[47]. Also the direct application of minocycline and rifampicin on titanium, placed in the distal
femur of a rabbit, lead to good results on prevention of device colonization and infection
prevention within a week after surgery [48]. A combined osteoconductive/antimicrobial
coating (HA/tobramycin) on titanium, evaluated in the proximal tibia of a rabbit indicated the
potential of a combined coating for infection prevention as well as implant incorporation [49].
A recent study on a combined osteoconductive/osteoinductive/antimicrobial coating
(HA/RGD/gentamicin) on stainless steel showed promising results on bone integration and
antibiotic release characteristics [33]. Furthermore antibiotic releasing coatings on biodegrad‐
able substances could replace antibiotic containing PMMA-beads, in this case no implant
coating would be necessary. A study on gentamicin coated poly(trimethylene carbonate)
(PMTC), a biodegradable polymer, showed good results on antibiotic release, biofilm inhibi‐
tion and biodegradability, suggesting to be a good substitute for PMMA-beads [50]. A recent
report on a prospective study of the first antibiotic releasing tibial nail has shown promising
clinical results with no deep surgical wound infections within the first six months after
implantation [51]. The major disadvantage for these coatings which they will face in the near
future is the increasing number of antibiotic-resistant bacterial strains. This is the main reason
why antimicrobial coatings, based on disinfectants or non-traditional antibiotics, are of great
interest in the research and development of such coatings.
3.2. Silver-based coatings
Silver is (amongst copper, lead and mercury) a potent antimicrobial heavy metal which has
been related to medicine for many centuries. Instead of its metallic state, only the ionic state
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of silver is considered to be antimicrobial and its mode of function is multifactorial. Ionic silver
not only reacts easily with amines and microbial DNA to prevent bacterial replication, but also
with sulfhydryl groups of metabolic enzymes of the bacterial electron transport chain,
resulting in their inactivation [52, 53]. This also forms its treat to large scale clinical applications,
since it can also inhibit eukaryotic metabolic function in a patient. Therefore a local release of
silver ions is preferable. In contrast to lead and mercury silver does not appear to have
cumulative toxic effects in the body, suggesting its potential as a coating component. The use
of silver in releasing coatings currently spans from central venous catheters to urinary tract
catheters and coated orthopaedic implants, with limited in vivo antimicrobial effectiveness as
a main problem. While some studies show that a silver coated surface can minimize the
infection risks by lowering the bacterial load [54-57], to date, pre-clinical studies and random‐
ized controlled trials of silver coated catheters, implants and external fixation pins were not
able to prove its antimicrobial efficacy [52, 58-61].
4. Coating evaluation
Newly developed coatings need evaluation before implementation in the clinic to prevent
possible adverse reactions to the coating. This evaluation includes mechanical testing and
cytotoxicity and biocompatibility tests. In general these tests can be subdivided in two
categories: in vitro and in vivo testing.
4.1. In vitro evaluation
This is defined as all testing modalities performed in controlled laboratory conditions, so
outside of a living organism or its natural setting (Table 3).
4.1.1. Cytotoxicity tests
Cytotoxicity tests can be subdivided in cell viability, cell adhesion and cell spreading assays
and are usually performed with fibroblastic cell lines (e.g. A529 [62], MC3T3-E1 [62-65], L929
[66], MG-63 [67, 68]). Cell viability assays evaluate the toxicity of a compound present in the
vicinity of the cells either in solution or in a solid state. During these tests the material to be
tested is incubated in cell culture medium. The resulting pre-conditioned culture medium is
then used for cell-culture to evaluate the viability of the cells after exposure to the extracted
medium from the material to be tested. Depending on the material, also direct cell culture on
the material surface can be performed. The viability of the cells can e.g. be assessed by
performing an MTT-assay.
• The MTT-assay is based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte‐
trazolium bromide (MTT, or another tetrazolium salt) to formazan by the enzyme succinate
dehydrogenase in the mitochondria of living cells. The formed purple product can be
measured spectrophotometrically and provides a direct measurement of the cell viability
based on mitochondrial activity, hence energy metabolism [55, 64-70].
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Ref. 
 
[55, 64-70] 
[64, 70, 71] 
[62] 
[72] 
[64, 68, 69, 73] 
[62] 
[62, 63, 69, 74] 
[65, 70] 
Detects 
 
Cell viability by metabolic activity 
 Reduction of a tetrazolium salt (yellow) to formazan (purple) by 
metabolically active cells 
 
Cell adhesion 
 Fluorescein diacetate→ cytoplasm of healthy cells (green) 
 DAPI → nuclei of every cell (blue) 
 
Cell viability by DNA content 
 DNA staining, released dye indicates level of cell viability 
compared to control situation 
Cell density based on protein content 
 protein staining, released dye indicates amount of cells present 
compared to control situation 
Actin staining 
 Rhodamine → actin cytoskeleton (red) 
 DAPI → nuclei (blue) 
Osteogenic cells → staining of calcium deposition (red) 
ALP activity is a marker for osteogenic potential of a cell 
 Enzymatic turnover of p-nitrophenyl phosphate to p-nitrophenol 
Cell viability 
 Fluorescein diacetate → cytoplasm of healthy cells (green) 
 Ethidium bromide → nuclei of death cells (red) 
Detection method 
 
Spectrophotometric 
Fluorescence 
Spectrophotometric 
Spectrophotometric 
Fluorescence 
Fluorescence 
Spectrophotometric 
 Enzymatic assay  
Fluorescence 
Analytical method 
Eukaryotic cultures 
Tetrazolium based assay 
 MTT 
 XTT  
 MTS 
FDA based assay 
 Fluorescein diacetate 
 DAPI 
 
Crystal violet 
SRB 
 Sulforhodamine B 
Phalloidinbased assay 
 Rhodamine 
 DAPI 
Alizarin Red S 
ALP 
 Alkaline phosphatase 
Live/dead staining 
 Fluorescein diacetate 
 Ethidium bromide 
Table 3. In vitro analytical methods – part 1
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• Cell adhesion assays evaluate the potential of an implant surface to allow cell adhesion by
culturing cells directly on the surface of the material to be tested. After allowing the cells to
adhere to the surface, non-adhering cells are washed of the implant surface after which the
adhering cells are double-stained with fluorescein diacetate (FDA) and ethidium bromide.
In this live/death staining, FDA will stain the cytoplasm of intact cells green, while ethidium
bromide will stain the DNA of dead cells red. The cell adhesion can be assessed by fluores‐
cence microscopy. The ratio between the FDA-positive and ethidium bromide-positive cells
provides insight into the live-dead percentage and thus biocompatibility of the culture
surface. If the cells are only incubated with FDA, cell lysis allows quantification by fluores‐
cence spectrophotometry. The level of fluorescent signal is an indication of cell adhesion on
the material surface [64, 70, 71].
• Cell spreading assays evaluate the potential of a surface to allow cell adhesion and
proliferation including matrix formation in the case of e.g. osteocytes. There are multiple
ways to assess this surface property. One of the methods described is the use of cell staining
directly on the surface after cell culture on the material surface by e.g. crystal violet staining
or by an actin staining based on phalloidin. The crystal violet staining is a DNA staining in
which cells are fixed on the cultured surface, then incubated with crystal violet to stain the
cellular DNA. After washing the stained cells the dye is released by the incubation in a weak
acid. The released dye can be measured on a spectrophotometer and providing a quantita‐
tive measure for the amount of cells present on the surface. A phalloidin-based staining
allows staining of the actin cytoskeleton and cellular organization on the surface of a
material. This is a direct cell staining which is visualized by fluorescence microscopy. In
most cases the phalloidin based stainings are counterstained with DAPI to stain the cells
nuclei, which allows visualization of the individual cells and their cytoskeleton [62, 64, 68,
69, 73].
• Assays to assess the osteogenic potential, quantify the osteogenic potential of a coating.
This can be determined by using cultured cells on the coating surface for an alkaline
phosphatase assay (ALP). The ALP assay determines the ALP activity within the tissue,
which is related to osteogenesis and bone deposition on the coating surface. Another method
to assess the osteogenic potential of a coated surface is an alizarin red s staining, which stains
calcified tissue [62, 63, 69, 74].
4.1.2. Antimicrobial coating tests
In the case of antimicrobial coatings the effect of the coating on bacteria can be assessed with
a wide variety of assays, with the most well-known being the agar diffusion test where the
release of an antimicrobial compound into the agar leads to an inhibition zone around the
releasing material.
• Bacterial viability can be assessed by a minimal inhibitory concentration (MIC)/ minimal
bactericidal concentration (MBC) assay. In this assay the releasing material is allowed to
release its effective compound into a buffer or culture medium over a certain time span. The
acquired pre-conditioned buffer/medium is then used in a bacterial culture setting in which
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a standardized amount of bacteria is exposed to the preconditioned buffer/medium. After
24 hours of incubation the optical density can be measured at 600 nm, the lowest concen‐
tration which shows no increased optical density compared to the uncultured control
condition defines the MIC, while the lowest concentration which shows no bacterial growth
after incubation of the MIC-cultures on agar plates for another 24 hours defines the MBC
[55].
• In vitro biofilm formation on a surface can be confirmed by incubating the surface in a
bacterial suspension, rinsing the surface with an isotonic buffer (PBS) and use sonication to
release the bacteria from the surface for quantitative culture. Or fix the bacteria on the surface
with 2.5% glutaraldehyde/PBS for evaluation with SEM. This method can easily be trans‐
ferred to the in vivo situation.
• International standards provide guidelines of how to assess coating stability and function,
e.g. ISO 10993-5 provides guidelines for in vitro medical device evaluation. The Japanese
Industrial Standard Z 2801 (JIS) describes a test for contact killing by the incubation of
bacteria on a potential antimicrobial surface. Culturing of this surface provides insight on
the antimicrobial properties of the evaluated coating [70, 73]. The American Standard E-2810
(American Society for Testing and Materials, ASTM)) describes a test for contact killing by
the application of a bacteria loaded agar onto the coated surface, after incubation the number
of viable bacteria is determined [70].
4.2. In vivo evaluation
This is defined as all testing modalities performed in a controlled group of living organ‐
isms, often including clinically relevant parameters and a broad range of imaging techni‐
ques (Table 4).
The first models concerning orthopaedic conditions date back to the late 19th century, primarily
focusing on osteomyelitis [77]. Rodet described 2 basic methods to establish an osteomyelitis
in a rabbit, the first one by inflicting a fracture and subsequent intravenous injection of the
bacterium, resulting in an osteomyelitic leasion in the area of the fracture. The second method
was performed by merely injecting bacteria intravenously, which resulted in a systemic
infection with periosteal leasions leading to local osteomyelitis [77].
The most well-known model for osteomyelitis is the model by Norden et al.; this model
describes the direct percutaneous injection, directly into the tibial intramedullary cavity of a
rabbit, of both a scleroting agent (sodium morrhuate, bile salts from codfish) and S. aureus [78].
Andriole et al. however, established one of the first osteomyelitis models with a foreign object.
Their model was based on a tibial fracture and subsequent tibial stabilization by a stainless
steel pin, contaminated with S. aureus [79]. Together with the model by Norden, the model of
Andriole mainly form the basis for current animal models used for the evaluation of implant
coatings. In general, rabbits are still the most frequently used animal species for these exper‐
imental studies, but there have also been successful models in mice, rats, dogs and sheep.
During the years, models increased in complexity and included multifactorial parameters.
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The bone bonding properties of apatite-coated implants were first evaluated in dogs by
Geesink et al. [16]. After the development of these apatite-coated implants, Vogely et al.
described a rabbit proximal tibial model for the evaluation of hydroxyapatite coated titanium
implants in an implant site infection [80]. Darouiche et al. were one of the first who described
a rabbit lateral femoral condyle model for the evalauation of antimicrobial coatings on titanium
[48]. Poultsides et al. described a haematogeneous implant contamination model by MRSA
[81]. Moojen et al. evaluated a combined coating with both osteoconductive (periapatite) and
antimicrobial (tobramycin) properties in a proximal tibial implant infection model in rabbits
[49]. Also, Moskowitz et al. developed antibiotic multilayer implant coatings with an antibiotic
release of over 4 weeks in a 2 stage rabbit distal femoral condyle infection model. The first
surgical stage contained the initial infection with the insertion of a pre-colonized peg, the
second surgical stage was the removal of the peg and implantation of the antibiotic coated
implant [65]. Alt et al. was one of the first to describe a coating which combined osteoconductive
(hydroxyapatite), osteoinductive (RGD) and antibiotic (gentamicin) properties in an experi‐
mental rabbit implant infection model [33].
4.2.1. Clinical parameters
Body weight and temperature provide general information about the animal’s physical
condition, with weight loss and fever in case of an infection. Leucocyte differentiation provides
a detailed overview of the percentages of lymphocytes, neutrophillic granulocytes, monocytes,
basophilic granulocytes and eosinophilic granulocytes in the total leucocyte population. An
elevated number of leucocytes or a shift in differentiation indicates a bacterial infection. The
ESR is based on the fibrinogen balance in the blood. In case of an inflammation or infection
the fibrinogen levels increase, resulting in agglutination of erythrocytes with sedimentation
as a result. CRP is an acute phase protein whose levels rapidly increase in case of inflammation
or infection. ESR and CRP both only indicate the presence of inflammation or infection, never
the cause or the location [82].
4.2.2. Imaging modalities
• Optical imaging (based on fluorescence and bioluminescence) is based on the detection
of light emitted from the body. The use of fluorescently labeled antibodies results in a very
specific signal, although resulting in a very local detection, it also requires a large amount
of antibodies when used in humans. This renders large scale use in humans not yet profitable
[76]. Also bioluminescence can be used to visualize infection. The main disadvantage of
bioluminescence is the requirement of the luciferase gene in the cell to be detected, meaning
the use of genetically modified organisms in case of detection by either autologous cells or
bacteria. E.g. a bacterium expressing luciferase can be used to monitor an implant infection
initiated with that bacterium [76]. Both methods are currently available in laboratory animal
setting.
• X-ray is by far the oldest imaging technique and the most frequently used imaging technique
to assess fractures, implant fixation, location and loosening, but also for the differential
diagnosis of bone diseases like osteomyelitis. The use of X-rays is cost effective, they are
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easy to obtain and have a relatively low burden for the patient. An X-ray only provides
detailed information about the mineralized tissue (or the lack thereof) and the disease
related changes accompanied with it [15, 83, 84].
• CT (computed tomography) is a 3D-imaging technique which uses X-rays to construct a 3D
image of the mineralized tissue in a patient. It generally provides more in-depth data about
the density of the mineralized tissue and bone remodeling compared to X-rays, however
imaging of metallic implants can result in scattering of the X-rays resulting in a blur around
the implant, rendering data-analysis difficult [76, 85, 86].
• DEXA (dual energy X-ray absorptiometry) is often incorrectly stated as a bone scan. The
use of 2 different energy levels of the X-ray beam allows accurate determination of the bone
mineral density. DEXA is the most common imaging technique to diagnose osteoporosis
and is seldomly used in in vivo coating assessment studies [86].
• MRI (magnetic resonance imaging) does, in contrast to other imaging techniques, not rely
on ionizing radiation but on the magnetic spin of protons. Due to the high water content
(and thus protons) of soft tissue, MRI is one of the main imaging techniques to assess the
musculoskeletal tissues, like cartilage and tendons. MRI only allows indirect imaging of
bony structures due to the limited water content of the bone. The main drawbacks for MRI
are the duration of the imaging acquisition and the inability for it to be used in combination
with metallic implants [76, 84].
• PET (positron emission tomography) is based on the detection of the annihilation event of
a positron with an electron (beta-decay). Every annihilation-event results in 2 gamma-
photons in an opposite direction from the point of decay. The detections of the photons on
the detectorring of the scanner results in a 3D image [97]. 18F is one of the most frequently
used isotopes (connected to a carrier molecule) to serve as a PET-tracer in orthopaedic
research. 18F-fluorodeoxyglucose (FDG) is used for the detection of infection and inflam‐
mation (figure 2) and 18F-fluoride as a tracer for bone remodeling [85, 94, 98]. With signal
specificity as its advantage, PET does not provide anatomical information, merely the
location of the tracer uptake. This is the main reason why PET and CT are often combined
in the clinic.
Figure 2. FDG PET of an uninfected implant versus an infected implant in the proximal part of a rabbit tibia, six weeks
after surgery. The increased tracer uptake around the infected implant (black area) depicts the local osteomyeliticlea‐
sion.
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Ref. 
 
[49, 78, 79, 81, 
87] 
[49, 81] 
[49, 78, 80, 81, 
88] 
[84] 
[49, 65, 78, 80, 
81, 84, 88] 
Detects 
 
General physical condition 
 Weight loss after surgical intervention, returns to pre-
operative values within first weeks after intervention.  
 Persistent weight loss indicates animal discomfort, 
infection or another systemic event related to device or 
intervention. 
General physical condition 
 Post-operative thermal elevation, returns to normal within 
days after surgery. 
 Persistent elevation indicates infection or another systemic 
event related to device or intervention. 
Infection by increase of erythrocyte sedimentation  
 Elevation in first post-operative week due to surgical 
intervention. 
 Remains elevated in case of infection. 
Infection by increase of CRP levels 
 Elevation in first post-operative week due to surgical 
intervention. 
 Remains elevated in case of infection. 
Infection by shift in leucocyte distribution 
 ↑ Neutrophils and monocytes → bacterial infection 
 ↑ Lymphocytes → viral infection or tumor 
 ↑ Basophils and eosinophils → inflammatory processes 
and/or allergic reactions 
Detection method 
 
Weighing scale 
Thermal probe 
Anticoagulated blood 
 Capillary tube 
Serum/plasma 
 ELISA 
Anticoagulated blood 
 Cell count 
Analytical method 
Clinical parameters 
Body weight 
Temperature 
ESR 
 Erythrocyte sedimentation rate 
CRP 
∙ C-reactive protein 
Leucocyte count and 
Leucocyte differentiation 
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Ref. 
 
[76] 
[33, 49, 76, 78-
81, 84, 87-94] 
[76, 84, 86, 88, 
91, 94] 
[86] 
[76, 84, 88] 
[84, 88, 95] 
[76, 88] 
[76, 84, 88, 91-
94] 
Detects 
 
Presence of light emitting cells  
 Fluorescence → GFP 
 Bioluminescence → luciferase 
 
Bone, bone pathology and metal objects 
Bone, bone pathology and metal objects 
Bone density 
 Difference in signal between both X-rays allows calculation 
of bone density 
Soft tissue 
 Detection of tissues with a high water content 
 
Active bone remodeling 
 99mTc –MDP → increased osteogenesis 
 67Ga-citrate → leucocyte activation (e.g. infection) 
Active bone remodeling 
 99mTc –MDP → increased osteogenesis 
 67Ga-citrate → leucocyte activation (e.g. infection) 
Active bone remodeling and infection 
 18F-Fluorodeoxyglucose → inflammation and infection 
 18F-Sodiumfluoride → active bone remodeling 
Detection method 
 
Fluorescence  or bioluminescence 
 Fluorescence  emission after excitation 
 Bioluminescence  auto-emission 
Electromagnetic radiation 
Electromagnetic radiation 
 X-ray (3D) 
Electromagnetic radiation 
 Dual energy X-ray of same object 
 
Nuclear magnetic resonance 
 Proton magnetic spin resonance (3D) 
γ-radiation 
 Single photon emission (2D) 
γ-radiation 
 Single photon emission (3D) 
γ-radiation  
 Positron mediated dual photon emission 
(3D) 
Analytical method 
Imaging modalities 
Optical imaging  
X-ray 
CT 
 Computed tomography 
DEXA 
 Dual energy X-ray absorptiometry 
 
MRI 
 Magnetic resonance imaging 
Bone scintigraphy 
SPECT 
 Single photon emission computed 
tomography 
PET 
 Positron emission tomography 
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Ref. 
 
[96] 
[33, 49, 75, 79-
81, 84, 87, 90-
94] 
[65, 80] 
[48, 49, 65, 78-
81, 84, 87, 89-
94] 
Detects 
 
Calcium deposition during bone remodeling (color) 
 Calcein blue → blue 
 Calcein green → green 
 Tetracycline → yellow 
 Xylenol orange → orange/red 
 Alizarin red S → red 
Tissue specific staining (including bacteria)  
 Haematoxylin/eosin staining (general) 
 Masson Goldnertrichrome staining (general) 
 Gram staining (bacteria) 
 Wear particles (e.g. polyethylene by polarized light) 
 Immunostaining (antibody specific) 
 
Surface treatment, bacterial biofilm, wear particles 
 Surface assessment of non-metallic substrates by gold or 
carbon sputtering 
 Metallic substrates can be assessed directly 
 
Bacterial growth under specific circumstances 
 Quantification by colony count or OD 600 measurements 
Detection method 
 
Fluorescence (excitation/emission) 
 Calcein blue (370 / 435 nm) 
 Calcein green (470 / 530 nm) 
 Tetracycline (390 / 570 nm) 
 Xylenol orange (470 / 610 nm) 
 Alizarin red S (550 / 620 nm) 
Light microscopy 
Electron microscopy 
(Selective) culture media 
 Tryptic soy agar/broth 
 Tellurite glycine agar (selective for 
coagulase negative Staphylococci) 
 
Analytical method 
Other – Ex vivo 
Calcium binding fluorophores 
 Calcein blue 
 Calcein green 
 Tetracycline 
 Xylenol orange 
 Alizarin red S 
Histology 
 Paraffin 
 PMMA 
SEM 
 Scanning electron microscopy 
Bacterial/bone culture 
 Tissue swaps 
 Bone homogenates 

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• A bone scan (bone scintigraphy) is based on the direct detection of gamma radiation
originating from the injected tracer molecule (often 99mTc, 67Ga or 111In) connected to a specific
ligand which allows tissue specific binding and thus imaging. A bone scan provides two-
dimensional images of the patient, which are sufficient in the clinic for the diagnosis [84].
• SPECT (single photon emission computed tomography) on the other hand allows acquisi‐
tion of three-dimensional images, providing more insight in size and localization of certain
pathology. In general, bone scan/SPECT-tracers have a longer half-life than PET tracers
making them more cost-effective to produce. Just like PET, SPECT provides limited
anatomical information and is therefore often combined with CT in the clinic [76].
Figure 3. The use of calcium binding fluorophores, depicted in 50 micron PMMA sections, of a rabbit tibial intrame‐
dullary nail model, to address normal bone remodeling and bone remodeling in case of an implant infection. Calcein
green was injected at 2 weeks, xylenol orange at 4 weeks and calcein blue at 6 weeks. In the case of normal bone
remodeling, calcium deposition is detected around the implant, combined with bone remodeling of the cortical wall.
In case of an implant infection the most calcium deposition is located in the outer cortical wall depicting the periosteal
elevation and calcification during the 6 week follow-up.
4.2.3. Ex vivo analysis
• Calcium binding fluorophores (like calcein green, blue and xylenol orange) are being used
for the in vivo labeling of the calcium deposition at the time of injection. The use of different
fluorophores, emitting at different wavelengths, allow post-mortem visualization of the
calcium deposition during the experimental follow-up [96]. This provides the opportunity
to determine implant ingrowth and bone remodeling in a normal healthy situation and
periosteal elevation and calcification during the progression of an osteomyelitis (Figure 3).
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• Histology is a commonly used method to assess the tissue in the implant area on e.g. tissue
morphology or bacterial presence. Tissue sections with metallic implants generally require
embedding in methylmethacrylate, instead of paraffin, with the inability to allow immu‐
nostainings as a major drawback. Still it provides the unique opportunity to assess the tissue-
implant interface [33, 49, 57, 80].
• Electronmicroscopy allows analysis of the implant surface (with or without coating) after
distraction from the surrounding tissue. This can include analysis of the bone matrix-
implant interface but also analysis of a formed biofilm [31].
5. Conclusion
Both osteointegration and infections are of concern in implants and prosthesis used in the field
of orthopaedic and trauma surgery. Metallic alloys used for plating and nailing of fractures
and joint replacements are the largest group of these implants. Hydroxyapatite coatings have
proven to be successful to promote osseous integration of uncemented total hip prosthesis.
During the last years the focus on coating development has shifted from osteoconductive
coatings (like hydroxyapatite) towards osteoinductive coatings to support bone remodeling
(like RGD and BMP coatings) and antimicrobial coatings for implant infection treatment and
prophylaxis (like silver or antibiotic releasing coatings).
Plasma spraying is the most used and accepted method for hydroxyapatite coatings. Other
coating techniques which do not require high temperatures are necessary for the application
of bioactive coatings that promote osteogenesis and/or prevent infections.
With the current palette of in vitro (e.g. MTT, ALP and SEM), in vivo (e.g. ESR, CT and PET)
and ex vivo techniques (e.g. bacterial culture, calcium binding fluorophores and histology), we
can thoroughly evaluate novel implant coatings in a qualitative and quantitative fashion. The
strength of such an evaluation will always lie in the combination of the individual methods,
leading to a complete, broad-spectrum analysis on coating toxicity and efficacy.
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